Mr. Justin Hanka reports

MINDBIO DEPLOYS NEW TECHNOLOGY INTOX COLLECT(TM); EXPANDS CNS DRUG DETECTION CAPABILITIES WITH VOICE & FACIAL RECOGNITION

Mindbio Therapeutics Corp. has completed the development of new technology Intox Collect, which has enabled the company to rapidly scale its collection and analysis of data samples (including voice and facial recognition data) from a wide range of substances when consumed.

Intox Collect is a novel software that has enhanced the company's data collection, testing and analytical capabilities for a range of stimulants and depressants of the human central nervous system.

In a world first, Mindbio has developed an AI (artificial intelligence) model that uses over 50 million data points (with that number expected to triple in the coming months) to predict drug and alcohol intoxication with remarkable accuracy, just by using the human voice. The completion of the company's new Intox Collect software allows the company to expand its prediction technology to a range of substances that affect the central nervous system, which, when consumed, impair cognition and human performance.

The technology is a game changer for intoxication detection, particularly where drug and alcohol testing is mandated by regulators, such as the mining, aviation and construction industries, and where high-volume testing at scale for a variety of drugs and alcohol presents major challenges and is time consuming, physically invasive and expensive.

The company recently announced that a prototype design for its new Edge AI hardware-software solution is nearing completion and its kiosk touch screen devices will be ready for testing late in Q2 2026. The development is assisted by the recent upsizing and completion of private placement to up to $1.5-million.

The company's chief executive officer, Justin Hanka, said: "The digital health diagnostics market represents a significant opportunity for Mindbio to leverage its diagnostics technology with a first-mover advantage in speech analytics for drug and alcohol intoxication detection. Our technology gives us a significant advantage in using voice to develop non-invasive health diagnostic tools."

Correction to prior news release

The company wishes to correct the disclosure in its news release dated April 1, 2026, announcing the closing of its private placement offering. In connection with completion of the offering, the company paid aggregate cash finders' fees of $74,983.97 and issued an aggregate of 124,973 non-transferable share purchase warrants to eligible third parties that introduced subscribers to the offering. Each finder warrant entitles the holder thereof to acquire one share at a price of 80 cents for a period of 36 months after the date of issue, subject to accelerated expiry in the event the closing price of the shares on the Canadian Securities Exchange exceeds $1 for 10 consecutive trading days. All other disclosure in the April 1, 2026, news release remains unchanged.

About Mindbio Therapeutics Corp.

Mindbio is a biotechnology company that is commercializing AI prediction technologies for drug and alcohol intoxication detection through voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The company is developing an enterprise platform, including Edge-AI kiosks integrating bespoke hardware and software, for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments, including the mining industry, aviation, construction and law enforcement.

We seek Safe Harbor.